insights_auto
Why is MVIR up 5.77%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEKÂ 1.69
arrow_upward
+5.77%(+0.092) 1D
Oct 2, 5:29:51 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEKÂ 1.71
High
SEKÂ 1.78
Low
SEKÂ 1.67
Mkt. cap
1.06B
Avg. vol.
1.88M
Volume
2.72M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
Open
SEKÂ 1.71
High
SEKÂ 1.78
Low
SEKÂ 1.67
Mkt. cap
1.06B
Avg. vol.
1.88M
Volume
2.72M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
News stories
From web sources and news partners
RealClearMarkets
·
53 minutes ago
Here Are the Corporations Joining S&P 500
TradingView
·
12 hours ago
Nasdaq rises for the week as Lumentum leads gains
BigGo Finance
·
11 hours ago
Dow extends gains, rises 250 points to 51,176 as jobs report cools rate-hike bets
U.S. Global Investors
·
12 hours ago
Gold Stumbled in September, but Gold Miners Beat Every Sector in the S&P 500
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB